Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients

J. Kovacova, J. Juracek, A. Poprach, J. Kopecky, O. Fiala, M. Svoboda, P. Fabian, L. Radova, P. Brabec, T. Buchler, O. Slaby,

. 2019 ; 16 (5) : 353-359. [pub] -

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20005967

BACKGROUND/AIM: Sunitinib is a tyrosine kinase inhibitor routinely used as first-line therapy in metastatic renal cell carcinoma (mRCC). Emerging evidence suggests that microRNAs (miRNAs) could be suitable biomarkers with predictive potential in mRCC. The aim of this study was to identify miRNA-based predictive biomarkers of therapy response to avoid unnecessary therapy to non-responding patients. PATIENTS AND METHODS: High-throughput miRNA microarray profiling was performed on a cohort of 47 patients treated with sunitinib. Validation of candidate miRNAs was carried out on an independent cohort of 132 mRCC patients using qRT-PCR. RESULTS: Out of 158 miRNAs (65 down-regulated, 93 up-regulated), six miRNAs were chosen for independent validation and miR-376b-3p was confirmed to be differentially expressed in tumors of patients with primary resistance versus long-term response (p<0.0002). CONCLUSION: A predictive miRNA associated with progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib was identified.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20005967
003      
CZ-PrNML
005      
20200526134046.0
007      
ta
008      
200511s2019 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/cgp.20140 $2 doi
035    __
$a (PubMed)31467229
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Kovacova, Julia $u Masaryk University, Central European Institute of Technology, Brno, Czech Republic.
245    10
$a MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients / $c J. Kovacova, J. Juracek, A. Poprach, J. Kopecky, O. Fiala, M. Svoboda, P. Fabian, L. Radova, P. Brabec, T. Buchler, O. Slaby,
520    9_
$a BACKGROUND/AIM: Sunitinib is a tyrosine kinase inhibitor routinely used as first-line therapy in metastatic renal cell carcinoma (mRCC). Emerging evidence suggests that microRNAs (miRNAs) could be suitable biomarkers with predictive potential in mRCC. The aim of this study was to identify miRNA-based predictive biomarkers of therapy response to avoid unnecessary therapy to non-responding patients. PATIENTS AND METHODS: High-throughput miRNA microarray profiling was performed on a cohort of 47 patients treated with sunitinib. Validation of candidate miRNAs was carried out on an independent cohort of 132 mRCC patients using qRT-PCR. RESULTS: Out of 158 miRNAs (65 down-regulated, 93 up-regulated), six miRNAs were chosen for independent validation and miR-376b-3p was confirmed to be differentially expressed in tumors of patients with primary resistance versus long-term response (p<0.0002). CONCLUSION: A predictive miRNA associated with progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib was identified.
650    _2
$a senioři $7 D000368
650    _2
$a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a karcinom z renálních buněk $x farmakoterapie $x patologie $7 D002292
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikro RNA $x genetika $7 D035683
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a sunitinib $x farmakologie $x terapeutické užití $7 D000077210
655    _2
$a časopisecké články $7 D016428
700    1_
$a Juracek, Jaroslav $u Masaryk University, Central European Institute of Technology, Brno, Czech Republic.
700    1_
$a Poprach, Alexandr $u Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Kopecky, Jindrich $u Department of Clinical Oncology and Radiotherapy, University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Fiala, Ondrej $u Department of Oncology and Radiotherapeutics, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Svoboda, Marek $u Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Fabian, Pavel $u Masaryk Memorial Cancer Institute, Department of Oncological and Experimental Pathology Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Radova, Lenka $u Masaryk University, Central European Institute of Technology, Brno, Czech Republic.
700    1_
$a Brabec, Petr $u Institute for Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.
700    1_
$a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.
700    1_
$a Slaby, Ondrej $u Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic on.slaby@gmail.com.
773    0_
$w MED00180194 $t Cancer genomics & proteomics $x 1790-6245 $g Roč. 16, č. 5 (2019), s. 353-359
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31467229 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200526134042 $b ABA008
999    __
$a ok $b bmc $g 1524825 $s 1096023
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 16 $c 5 $d 353-359 $e - $i 1790-6245 $m Cancer genomics & proteomics $n Cancer Genomics Proteomics $x MED00180194
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace